Nervonik
Nervonik is a California-based medical technology company pioneering the development of the smallest, most advanced, and power-efficient neuromodulation implants for chronic neuropathic pain. Their mission is to provide a more effective, non-narcotic alternative to opioids and complex spinal-cord stimulators, leveraging next-generation neural-sensing integrated circuits and wireless power transfer technology. Nervonik's solutions are designed to deliver optimized, personalized therapy with minimal resistance, aiming to dramatically improve the quality of life for patients suffering from chronic pain.
Nervonik
What We Do
Tiny, power-efficient neuromodulation implants designed to target the peripheral nervous system, offering a narcotic-free, long-term solution for chronic pain. Features include wireless power transfer, minimally invasive implantation, and digital app integration. Available for research and veterinary use.
Breakthrough pain-therapy medical devices for research and veterinary purposes, with expected regulatory approval for human use soon.
Development and provision of advanced neuromodulation implants targeting the peripheral nervous system (PNS) for the treatment of chronic neuropathic pain. These devices are currently available for research and veterinary use while pursuing FDA approval for human use.
Provision of a digital app to wirelessly adjust implant settings and collect data for sharing with medical professionals, enabling personalized and adaptive therapy.
Regenerative Medicine
Key People
CEO, Founder, and Board Member
Chief Clinical Advisor
Chief Operating Officer
Chief Scientific Officer
General Counsel
Patent Counsel
News & Updates
Successfully completed the first-in-human clinical study of its proprietary PNS device for chronic pain, demonstrating safety and device performance.
Received regulatory approval to conduct a first-in-human feasibility study with its novel PNS technology for chronic pain.
Details the successful completion of Nervonik's first-in-human clinical study for its PNS device, highlighting the technology's safety, performance, and potential to improve chronic pain therapies.
Announces Nervonik's regulatory approval to begin a first-in-human feasibility study with its proprietary PNS technology for chronic pain.
Nervonik successfully completed its first-in-human clinical study of its proprietary PNS device, marking a significant milestone in the development of neurotechnology-based therapies for chronic pain. The study was conducted at Punta Pacifica Hospital in Panama City, Panama, and involved patients with chronic shoulder or knee pain. Results are to be presented in early 2025.
Nervonik received regulatory approval to conduct a first-in-human feasibility study of its novel PNS technology, focusing on chronic pain of peripheral nerve origin. Enrollment is anticipated to begin in Q3 2024, with results to follow.